Stimulant prescription cautions: addressing misuse, diversion and malingering.
about
The Potential for Misuse and Abuse of Medications in ADHD: A Review"It has to be fixed": a qualitative inquiry into perceived ADHD behaviour among affected individuals and parents in Western Australia.Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trialsThe use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.Peak ages of risk for starting nonmedical use of prescription stimulantsThe Development of an Embedded Figures Test for the Detection of Feigned Attention Deficit Hyperactivity Disorder in AdulthoodAssessment of effort in children: a systematic review.Addressing the problem of ADHD medication as neuroenhancements.Detection of feigned attention deficit hyperactivity disorder.ADHD symptomatology is best conceptualized as a spectrum: a dimensional versus unitary approach to diagnosis.ADHD in school-aged youth: Management and special treatment considerations in the primary care setting.Non-Medical Use of Prescription Stimulants: A Comparison of College Students and their Same-Age Peers Who Do Not Attend College.Misuse of Methylphenidate.Acute and long-term effects of adolescent methylphenidate on decision-making and dopamine receptor mRNA expression in the orbitofrontal cortex.Faking ADHD? Symptom Validity Testing and Its Relation to Self-Reported, Observer-Reported Symptoms, and Neuropsychological Measures of Attention in Adults With ADHD.Physician Perceptions of ADHD Stimulant Diversion and Misuse.Assessing ADHD symptoms in children and adults: evaluating the role of objective measures.Addictive potential of novel treatments for refractory depression and anxiety.
P2860
Q22241206-FE4D65AF-6470-4EF0-80F4-99CB5407EA19Q27306703-E84ACCC8-9DC7-44D5-88E5-343F4A39FA54Q28553322-2E5E87A4-92E5-4768-8F80-61C05B497685Q34673021-7AA47E23-7948-444F-BD2D-7F0C183284BAQ35690420-FE6588D1-4542-4761-8975-BF7C223CAC3CQ36161447-810D55A4-8E27-4B4F-876F-6B7518C5188CQ38171838-1DE4342F-8E36-486B-9C15-3DEA6D98EB5CQ38205021-C5558163-0B35-456A-9770-7D3F0C07F614Q38237277-61419858-7CA7-484C-AFDC-8BC4DCBF8593Q38468989-34384C3F-714D-4185-90CF-6ED7910BE3A1Q38808573-377510D5-4B56-44C3-BE35-D5D0CA048368Q38829728-0FE6ABEC-6293-45DD-8983-F84C3F3E234CQ40180283-31749D0D-7E0C-4F64-A975-8C9A1A13D82CQ48303711-024C23B4-4316-49B2-9A63-8F412E7FE35CQ50717614-252FEB10-8CA7-4A5C-88C1-A28F1D3135E2Q53157750-3FDB4490-6134-459F-94E5-6B697AF612C8Q55224792-BC773D28-8026-49D7-9D05-DB91C5B680CFQ55334438-FF4C5BDF-C34F-4581-8565-153A2FE46F47
P2860
Stimulant prescription cautions: addressing misuse, diversion and malingering.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Stimulant prescription cautions: addressing misuse, diversion and malingering.
@en
type
label
Stimulant prescription cautions: addressing misuse, diversion and malingering.
@en
prefLabel
Stimulant prescription cautions: addressing misuse, diversion and malingering.
@en
P2860
P1476
Stimulant prescription cautions: addressing misuse, diversion and malingering.
@en
P2093
David L Rabiner
P2860
P2888
P356
10.1007/S11920-013-0375-2
P407
P577
2013-07-01T00:00:00Z
P6179
1035971442